Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.

Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, Narum DL, Miles AP, Orcutt AC, Muratova O, Moretz SE, Zhou H, Diouf A, Fay M, Tierney E, Leese P, Mahanty S, Miller LH, Saul A, Martin LB.

PLoS Clin Trials. 2007;2(4):e12. Epub 2007 Apr 6.

2.

The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms.

Saxena AK, Singh K, Su HP, Klein MM, Stowers AW, Saul AJ, Long CA, Garboczi DN.

Nat Struct Mol Biol. 2006 Jan;13(1):90-1. Epub 2005 Dec 4.

PMID:
16327807
3.

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.

Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, Singh S, Martin LB, Wu Y, Giersing BK, Stowers AW, Long CA, Saul A.

Vaccine. 2005 Mar 31;23(19):2530-9.

PMID:
15752840
4.

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL.

Infect Immun. 2004 Feb;72(2):949-57.

5.

Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.

Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M.

Am J Trop Med Hyg. 2003 Nov;69(5):536-41.

PMID:
14695092
6.

Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Coban C, Ishii KJ, Stowers AW, Keister DB, Klinman DM, Kumar N.

Infect Immun. 2004 Jan;72(1):584-8.

7.
8.
9.

Structure of the C-terminal domains of merozoite surface protein-1 from Plasmodium knowlesi reveals a novel histidine binding site.

Garman SC, Simcoke WN, Stowers AW, Garboczi DN.

J Biol Chem. 2003 Feb 28;278(9):7264-9. Epub 2002 Dec 19.

10.

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH.

Infect Immun. 2002 Dec;70(12):6961-7.

11.

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW.

Infect Immun. 2002 Dec;70(12):6948-60.

12.
13.

Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

Miles AP, Zhang Y, Saul A, Stowers AW.

Protein Expr Purif. 2002 Jun;25(1):87-96.

PMID:
12071703
14.

Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.

Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW.

J Infect Dis. 2002 Mar 1;185(5):657-64. Epub 2002 Feb 14.

PMID:
11865423
16.

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.

Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):339-44. Epub 2001 Dec 18.

17.

Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.

Hisaeda H, Collins WE, Saul A, Stowers AW.

Vaccine. 2001 Dec 12;20(5-6):763-70.

PMID:
11738740
18.
19.
20.

Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development?

Stowers AW, Miller LH.

Trends Parasitol. 2001 Sep;17(9):415-9.

PMID:
11530352
21.

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH.

Infect Immun. 2001 Mar;69(3):1536-46.

22.

Structural conformers produced during malaria vaccine production in yeast.

Stowers AW, Zhang Y, Shimp RL, Kaslow DC.

Yeast. 2001 Jan 30;18(2):137-50.

23.

Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC.

Infect Immun. 2000 Dec;68(12):6618-23.

24.
25.
26.

Preparative scale purification of recombinant proteins to clinical grade by isotachophoresis.

Stowers AW, Spring KJ, Saul A.

Biotechnology (N Y). 1995 Dec;13(13):1498-1503.

PMID:
9636309
27.

Plasmodium falciparum genetic diversity can be characterised using the polymorphic merozoite surface antigen 2 (MSA-2) gene as a single locus marker.

Prescott N, Stowers AW, Cheng Q, Bobogare A, Rzepczyk CM, Saul A.

Mol Biochem Parasitol. 1994 Feb;63(2):203-12.

PMID:
8008018

Supplemental Content

Loading ...
Support Center